Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 1.1%.
The iShares Biotechnology ETF (IBB) was down 1%.
In corporate news, Bristol Myers Squibb (BMY) told regulators, researchers and patient groups in early June that it had paused trials of its CAR-T treatment zola-cel in autoimmune disorders over potentially life-threatening side effects, The Wall Street Journal reported. Bristol Myers Squibb shares were falling 2.2%.
Novo Nordisk's (NVO) charitable foundation and its Quantum Foundry Copenhagen company are planning to set up a new 5,300 square meter quantum chip production facility in Copenhagen, the organizations said. Novo shares were down 2.1%.
Intellia Therapeutics (NTLA) shares added 0.8% after it said Friday it entered a $400 million non-dilutive senior secured term loan facility with OrbiMed to support clinical and commercial milestones.
Immuron (IMRN) shares surged 41% after the company announced Friday an exclusive distribution agreement for Probis in the US with Calmino.